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ABBREVIATIONS
AAH: Atypical Adenomatous Hyperplasia.
ADCC = Antibody Dependant Cell Cytotoxicity.
BAC = Bronchioalveolar Carcinoma.
COX = Cyclo-Oxygenase.
CSF-R1 = Colony Stimulating Factor-Receptor 1.
DC = Dendritic Cells.
DSS = Disease Specific Survival.
FNA = Fine Needle Aspiration.




M-CSF = Macrophage-Colony Stimulating Factor. 
MDSC = Myeloid Derived Suppressor Cells.
MHC = Major Histocompatibility Cmplex
NK = Natural Killer.
NSCLC = Non-Small Cell Lung Carcinoma.
SCLC = Small Cell Lung Carcinoma.
TGF = Transforming Growth Factor.
TAM = Tumor Associated Macrophages.
TIL = Tumor Infiltrating Lymphocytes.
TMA = Tissue Microarry.
TNF = Tumor Necrosis Factor.
Treg cells = T regulatory cells.
VEGF = Vascular Endothelial Growth Factor.
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1.1.1 Lung cancer incidence and clinical presentation
Cancer is a major public health problem worldwide and lung cancer is the leading 
cause of cancer death in the western world, including Norway (Figure 1). In some countries, 
lung  cancer  accounts  for  more  deaths  than  prostate  cancer,  breast  cancer,  and  colorectal 
cancer  combined.1 There  are  two  main  categories  of  lung  cancer:  Non  small  cell  lung 
carcinoma (NSCLC) (80%) and small cell lung cancer (SCLC) (20%).2 
   
      Figure 1: Age standardised mortality rates in Norway 2007 for selected cancers 
      (source: Statistics Norway), (from www.kreftregisteret.no). 
Lung  carcinomas  are  insidious lesions  that  more  often than not  have spread to  be 
unresectable before they produce symptoms. In few instances, chronic cough with sputum call 
attention to still localized, resectable tumors. When hoarseness, chest pain, superior vena cava 
syndrome, pericardial or pleural effusion, atelactasis or pneumonitis appear, the prognosis is 
grim. Often, the tumor presents with symptoms related to metastatic spread to the brain, liver 
or  other  organs.  Although  metastasis  to  the  adrenal  is  common,  adrenal  insufficiency  is 
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uncommon.  Clinical  manifestations  due to paraneoplastic  syndrome can also be seen (see 
table in appendix).
 At present, surgery remains the primary therapy modality for solid tumors, including 
NSCLC. However, despite the advancement in molecular knowledge and the introduction of 
multiple new therapeutic lung cancer agents, the dismal 5-years survival rate (<15%) remains 
relatively unaltered  (Figure 2),  with a  median  survival  still  less  than a  year.  The lack of 
advancement  reflects  the  limited  available  knowledge  about  factors,  which  promote 
oncogenic transformation and proliferation and progression of NSCLC cells. 
Nearly 75% of NSCLC patients have unresectable advanced disease with lymph nodes 
and/or visceral metastases at the time of diagnosis. Even among patients treated for stage I-III 
NSCLC and considered postoperatively tumour-free, about 65% will relapse within two years 
after surgery and subsequently die of metastatic spread.1 
Figure 2: Incidence (dark blue/red), mortality rate (light blue/pink) and 5-year survival  
(green/brown) proportions of lung carcinoma in Norway (source www.kreftregisteret.no).
1.1.2. Lung cancer etiology
There is overwhelming evidences that  tobacco smoking is the major cause of lung 
cancer,  and  the  geographical  and  temporal  patterns  of  lung  cancer  today  reflect  tobacco 
consumption 2-3 decades back. In fact, 80-90% of lung cancers are attributed to carcinogens 
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from cigarette smoking, and tobacco smoke contain 4800 chemical components, of which 20 
are oncogenes.3 However,  epidemiological  studies have shown that  no more than 11% of 
smokers  will  develop  this  disease,  suggesting  additional  environmental  and  ⁄  or  genetic 
determinants. Two groups of enzymes exhibit a genetic polymorphism that could play a role 
in lung cancer incidence: P450 enzymes, encoded by CYP family genes, and glutathione S 
transferase  (GST).  The  former  is  responsible  for  activation  of  tobacco  carcinogen 
intermediate metabolites, whereas the latter is able to detoxify them.4 Recently,  a nicotinic 
acetylcholine  receptor  gene  variant  (acetyl  choline  receptors  3  and 5)  at  15q24 has  been 
identified  and  is  suspected  of  being  responsible  for  a  higher  risk  of  lung  cancer  and/or 
nicotine addiction.4 Examples of other chemicals associated with lung cancer are in Table 1.







Chromium compounds Metal plating, pigments
1.1.3. Pulmonary preinvasive lesions
Three pulmonary pre-neoplastic lesions are identified to date5: 1) Squamous bronchial 
dysplasia  and carcinoma  in  situ  (CIS),  preceding  bronchial  squamous  cell  carcinoma and 
basaloid  carcinoma,  2)  atypical  adenomatous  hyperplasia  (AAH)  representing  the 
preneoplastic condition for a subset of adenocarcinoma, namely bronchioalveolar carcinoma 
(BAC),  and  3)  diffuse  idiopathic  pulmonary  neuroendocrine  cell  hyperplasia,  a  proposed 
precursor of carcinoid tumors. No morphological epithelial lesion has been identified to date 
as a precursor for SCLC. 
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1.1.4. Molecular genetics of lung cancer
Concomitant  to morphological  changes  from normal  epithelium to preneoplastic  to 
neoplastic lesions, multi-step accumulation of 10–20 genetic alterations occurs at the genomic 
level, leading to initiation, development and maintenance of lung cancer.
For  squamous  carcinoma,  allelic  losses  (loss  of  heterozygosity)  at  multiple  3p 
chromosome sites are the earliest change, followed by loss of heterozygosity at 9p21. Later 
changes include alterations at 8p21-23, 13q14, and 17p13.6 RAR (retinoic acid receptor) loss 
occurs  in  40 %  at  an  early  stage  (mild  dysplasia);  whereas  P53  mutation  and  vascular 
endothelial  growth factor (VEGF) overexpression occurs later on. Inactivation of p16 was 
demonstrated in 75 % of in situ carcinoma adjacent to invasive squamous cell carcinoma of 
the lung often associated with VEGF, cyclin D1 and E overexpression.5
Although the cell of origin for most adenocarcinomas remains unknown, peripheral 
adenocarcinomas arise from Clara cells  or type 2 pneumocytes,  and for a subset of these 
adenocarcinomas, they are preceded by AAH. Two different molecular pathways have been 
detected in lung adenocarcinoma pathogenesis (Figure 3): smoking-associated activation of 
RAS signalling, and non-smoking-associated activation of epidermal growth factor receptor 
(EGFR) signalling. KRAS codon 12 mutations are reported in 15% to 39% of AAH lesions, 
and p53 mutation has been demonstrated with increasing frequency in the progression from 
AAH through BAC to invasive adenocarcinoma.6 EGFR mutation stimulate PI3K/AKT cycle 
leading  to  carcinogenesis.  Finally,  there  is  no molecular  or  genetic  marker  to  distinguish 
diffuse idiopathic pulmonary neuroendocrine cell hyperplasia from reactive neuroendocrine 
proliferation,  but  allelic  imbalance  at  11q13,  where  the  tumor  suppressor  gene  MEN1 is 
located, is observed in up to 50% of typical carcinoids and 50–70% of atypical carcinoids.
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Figure 3.  Two main pathways proposed for the development of peripheral adenocarcinoma 
of the lung.
1.1.5. Lung cancer staging
All patients with suspected lung cancer undergo a chest x-ray and a CT of the chest 
including the upper abdomen with the adrenal glands. Tissue biopsies and/or brush cytology 
are  usually  obtained  by  bronchoscopy,  but  for  peripheral  tumors  CT  guided  fine  needle 
aspiration  (FNA)  cytology  and  biopsy  are  often  performed.  In  patients  with  enlarged 
mediastinal glands, mediastinoscopy or open surgery were regularly done to confirm or to 
rule  out  N2-status.  Today,  positron  emission  tomography  (PET),  transoesophageal  or 
endobronchial ultrasound as well as FNA via bronchoscopy have been added to the staging 
procedures. These procedures are vital for a correct staging, treatment and prognosis. Clinical 
TNM (cTNM) is  based  on  clinical  examination  of  the  patients  while  pathological  TNM 
(pTNM) is  based  on examination  of  the surgical  specimen.  The  novel  TNM lung cancer 
classification has defined new tumor size cut-off values,  (T1a, ≤ 2.0 cm; T1b, > 2.0 cm ≤ 
3.0cm; T2a, > 3.0 cm ≤ 5.0 cm; T2b, > 5.0cm  ≤ 7.0 cm; T3, > 7.0 cm).7 In addition, the M 
factor is also modified in the updated TNM classification (Table 2).7 Furthermore, the use of 
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special stain for elastic fibres is recommended in assessing pleural invasion8
Table 2: Modification of the M factor in the new, 7th edition staging system
TNM  stage  estimates  the  postoperative  outcome  as  well  as  rational  for  adjuvant 
therapy. Despite the prognostic power of this staging system, determining the outcome for 
patients with NSCLC has, however, remained inaccurate. The detection of micrometastasis in 
lymph nodes or in other locations might improve staging accuracy. However, it is uncertain if 
this  offers  a  prognostic  marker  for  recurrence.  Hence,  micrometastasis  detection  is  not 
included in  the  routine  staging process  of  NSCLC and using immunohistochemistry  with 
cytokeratin is not a routine test in examining the lymph nodes from NSCLC patients. 
1.1.6. Histopathology of NSCLC (Table 3 and Figure 4)
Other  than the distinction  between NSCLC and  SCLC, there has  historically  been 
limited  interest  in  further  histological  subtyping  of  NSCLC,  and the  staging  system was 
considered quite adequate. This perception has changed dramatically during the past decade 
with the evolution of novel therapies.  For example,  treatment  with EGFR tyrosine kinase 
inhibitors  is  more  efficacious  in  patients  who  were  never  smokers,  females  or  had 
adenocarcinoma  histology.9 Similarly,  the  new multitargeted  antifolate  agent,  Pemetrexed 
(Alimta) give best effect in adenocarcinoma.10 Therefore, how much longer the term NSCLC 
will be accepted as the bottom line on the pathological reports to the oncologists is uncertain.
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Adenocarcinoma is the most histologically heterogeneous form of lung cancer (Table 
3),  both  between  cases  and  within  individual  tumors,  and  this  has  implications  for 
pathologists reporting on this tumor type. Small biopsy samples may not be representative of 
the whole tumor or allow appreciation of much tumor architecture,  and the specificity for 
preoperative diagnosis of adenocarcinoma is less than 50%.11 The vast majority of pulmonary 
adenocarcinomas are heterogeneous tumors showing a mixture of patterns that probably have 
different  biological  behaviour  and  therefore  potential  therapeutic  implications  for  the 
patient.12 The value of subclassifying lung adenocarcinoma is still relatively uncertain, and 
our understanding of this area of tumor pathology is still evolving. A consistent, reproducible, 
biologically meaningful classification and pathological diagnosis of lung adenocarcinoma will 
facilitate comparison between case databases from different centres, be of great importance in 
epidemiological studies, and ensure that the patient receives the most appropriate treatment.12 
In  the  future,  oncologists  may require  more  than  a  simple  diagnosis  of  'adenocarcinoma' 
before proceeding with patient management. BAC is the only subtype of adenocarcinoma that 
has  been  classified  separately  in  our  study,  as  it  has  a  well-documented  prognostic 
significance. The WHO definition used to include a case in BAC category as ‘neoplastic cells 
growing along pre-existing alveolar structure without evidence of stromal, vascular or pleural 
invasion’.13
Squamous cell  carcinoma is seen as sheets or islands of large polygonal malignant 
cells  containing  keratin  (individual  cells  or  keratin  pearls)  and/or  intercellular  bridges; 
adjacent bronchial dysplasia or carcinoma in situ are common. Subtypes include: Papillary, 
clear cell, small cell and basaloid.2 No subtyping was used in our study.
 
13
Table 3: WHO classification of lung adenocarcinoma (2004). 
             Adopted from reference (adopted from ref. 12).
 
Large  cell  (anaplastic)  carcinoma  may  be  undifferentiated  squamous  cell  or 
adenocarcinomas.  It  is  a  diagnosis  by  exclusion  and  hence  cannot  be  diagnosed,  with 
certainty, on small biopsies. Microscopically, it is seen as large polygonal and anaplastic cells 
growing  in  solid  nests  without  obvious  squamous  or  glandular  differentiation;  vesicular 
nuclei, prominent nucleoli, moderately abundant cytoplasm and well defined cell borders. No 
morphological features of  neuroendocrine architecture are seen.13
1.1.7. Potential for new prognostic factors and therapeutic approach in NSCLC
To date the only relevant prognostic factor for including patients in therapeutic trials 
remains the TNM classification.14 Improving the survival rate for lung cancer patients requires 
the comprehension of all molecular events leading to lung cancer development including the 
significance of the immune system. The cancer research community anticipates
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Figure 4:  Major histological types of lung carcinoma.  Adenocarcinoma (A), squamous cell  
carcinoma (B),  bronchioalveolar carcinoma (C),  large cell  anaplastic carcinoma (D) and 
small cell carcinoma (E).
that an improved understanding of the genetic and epigenetic mechanisms driving the tumor 
may provide new tools for clinicians to stratify patients for optimizing therapy or assessing 
the  prognosis  within  the  same  subgroup  of  tumors  or  at  the  individual  level.  Improved 
understanding of NSCLC biology has recently led to the development  of new therapeutic 
agents  (e.g.  EGFR’ and VEGF inhibitors).  However,  the challenge  is  still  to  identify  the 
proper combination of agents for those novel therapies to enhance efficacy,  as well  as to 
increase the accuracy of prognosis prediction.
Increased  accuracy  of  prediction  of  relapse/metastases  might  be  obtained  by  non-
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tumoral  variables,  as  both  primary  tumor  and  metastasis  develop  within  a  tumor 
microenvironment which includes the inflammatory cells and mediators.15  Hence studying 
tumor microenvironment including the inflammatory component is paramount. 
1.2. The immune system
Our immune system is composed of two distinct  compartments;  the innate and the 
adaptive  immune  system.  Each  compartment  has  developed  advanced  communication 
networks, which enable rapid and effective responses to tissue injury.
1.2.1. The innate immune system
The uniqueness of this system is the inherent ability to rapid response when tissue 
injury occurs.  Consisting  of dendritic  cells  (DC),  natural  killer  (NK) cells,  macrophages, 
leukocytes (neutrophils, basophiles, and eosinophils), mast cells as well as soluble factors, the 
innate  immune  system is  the  first  line  of  defence  against  foreign  pathogens  (e.g.  virally 
infected cells or transformed cells). In the acute response, DCs, macrophages and mast cells 
are  the  primary  effectors,  as  they are  posted  in  the  tissue and supervise  its  environment. 
Macrophages  and  mast  cells  immediately  release  soluble  mediators  such  as  cytokines, 
chemokines,  matrix  metalloproteinases  (MMPs),  oxygen  species  and  bioactive  mediators 
(histamine) inducing mobilization and infiltration of additional leukocytes, angiogenesis and 
remodelling of the damaged tissue.16, 17 
1.2.2. The adaptive immune system
The  innate immunity response leads to activation of the more sophisticated adaptive 
immune system. Primary adaptive immune response requires direct interactions with mature 
antigen-presenting cells  as well  as a proinflammatory environment.  The adaptive immune 
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system is composed of B and T lymphocytes and antibodies. The two major T lymphocyte 
subsets  are  CD4+  helper  and  CD8+  cytotoxic  T  lymphocytes.  These  lymphocytes  are 
specialized cells  by expression of somatically generated,  diverse antigen-specific receptors 
allowing a flexible and broader repertoire of responses than the innate immune cells.18, 19
Primary  adaptive  responses  are  slower  than  the  innate  responses  since  clonal 
expansion  due  to  recognition  of  foreign  antigens  is  required  to  obtain  adequate  antigen-
specific B and T lymphocytes to fight the infection.20, 21 However, during the primary adaptive 
immune response subsets of lymphocytes differentiates to long-lasting memory cells with a 
heightened state of immune reactivity at subsequent exposures of the same antigen. 
1.2.3. Combined innate and adaptive immune responses (Figure 5)
The innate  immune system regulates  adaptive  immune responses  by production  of 
cytokines,  interactions  between  DCs  and  lymphocytes,  and  activation  of  the  complement 
system. The adaptive immune system modulates the innate immune responses by cytokine 
and antibody production.22 
Being a key player in the interphase between innate and adaptive immunity, DCs take 
up  foreign  antigens,  migrate  to  lymphoid  organs  and  present  these  antigens  to  adaptive 
immune cells.  NK cells  also participate  in the cellular  crosstalk between the two systems 
through  interacting  bidirectionally  with  DCs,  promoting  DC  maturation  and  eliminating 
immature DCs, thus reciprocally regulating activation of NK cells.23-25
Through interaction of all cellular components, the key role of the immune system is 
to maintain  tissue homeostasis.  But it  is,  however,  also implicated  in the pathogenesis  of 
several chronic diseases, also cancer.26
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Figure 5: Schematic presentation of the interplay between innate and adaptive immunity. NK  
T cells  and γδ T cells  play their  roles in the crossroad between the innate and adaptive  
immune system. The crosstalk  between these systems is  mediated by complex interactions  
between cells of both immune subsets and their soluble factors. The innate immune system, 
i.e. the first line of immune defense, regulates adaptive immune responses by the production  
of  cytokines,  interactions  between  dendritic  cells  and  lymphocytes  and  activation  of  the  
complement  system.  The adaptive  immune system modulates  innate  immune responses  by  
cytokine and antibody production. Adapted from de Visser et al.22 
1.3. Tumour Immunity
Malignant  transformation  is  a  complex  process  that  results  in  the  expression  of 
proteins that are seen as non-self by the immune system. The fact that cancers exist suggest 
that the immune surveillance is imperfect. The fact that some tumors escape these lines of 
defence does not, however, preclude the possibility that others may have been aborted.27 A 
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strong  argument  for  the  existence  of  immunosurveillance  with  respect  to  transformed  or 
malignant cells, is the increased frequency of cancers in immunodeficient hosts (e.g. AIDS 
patients).28
 The predominant host cells recruited to and/or activated in the vicinity of the tumor 
are  immune  cells,  fibroblasts  and  endothelial  cells.  Furthermore,  there  is  an  abundant 
collection  of  growth  factors,  pro-angiogenic  mediators,  cytokines,  chemokines  and 
components of the extra cellular matrix. There are increasing evidence indicating that many of 
the processes occurring in the tumor microenvironment are hijacked by the malignant tumor 
to  facilitate  its  progression.29 However,  the  results  of  several  studies  indicated  that  the 
immune system could be harnessed and directed as an anticancer  therapy.  This may be a 
reality if we gain a better understanding of its mechanisms of action in malignancy.30 
Cancers are often infiltrated by inflammatory cells (T and B lymphocytes, NK cells, 
DCs,  macrophages,  neutrophils,  eosinophils  and  mast  cells),  which  are  variably  scattered 
within  the  tumor  and  loaded  with  different  inflammatory  mediators.15 Tumor  infiltrating 
lymphocytes (TIL) are mostly T cells30, and cytotoxic T lymphocytes are capable of specific 
lysis of tumor cells. Tumor-specific CD4+ T cells can be isolated from various human solid 
tumors.31 Furthermore, selective expansion of tumor-specific CD8+ cells in a neoplasm is a 
probable  indication  of  an  ongoing  immune  response  in  various  tumors,  including  lung 
carcinoma.32, 33  
1.3.1. Inflammatory cells and cancer prognosis
The presence of different tumor infiltrating inflammatory cells has been correlated to a 
lower  tumor  stage  and  a  better  survival  in  a  variety  of  human  cancers  like  colorectal 
carcinoma34, squamous cell carcinoma of the esophagus35 and ovarian cancer36. In contrast, no 
such  correlation  was  found in  other  types  cancer  like  hepatocellular  carcinoma37,  and  an 
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association  with shorter  survival  was  reported in  renal  cell  carcinoma.38 In  many studies, 
distinction could not be made with respect to inflammatory cell localization, which may have 
caused the lack of significant results, as inflammatory cells in different tumor compartments 
(stromal vs. intraepithelial) may have different functions and roles in this respect. It was only 
after  such a categorization was done,  that  survival  effect  could be associated with in situ 
immunological  processes  in  some  studies.39 In  NSCLC,  the  published  results  are 
contradictory. While, some studies reported that a high number of some types inflammatory 
cells was associated with a better survival39, 40, others found no such correlation.41 
1.3.2. Antitumor effector mechanisms
Antitumor effectors are mediated by many mechanisms (Figure 6):
1.  Cytotoxic  T  lymphocytes as  evidenced  by  the  presence  of  major  histocompatibility 
complex (MHC)-restricted CD8+ cells within human tumors.30
2. Natural killer cells that can destroy tumor cells without prior sensitization. After activation 
by IL-2, NK cells can lyses a wide range of human tumors even if they appear not to be 
immunogenic for T cells. CD8+ T lymphocytes and NK cells seem to provide complementary 
antitumor  mechanisms.  Tumors  that  fail  to  express  MHC  class  I  antigens  cannot  be 
recognized by CD8+ T-cells, but NK cells,  which will lose the inhibition mediated by the 
recognition of normal autologous class I molecules, can trigger them.42
3. Humoral mechanisms mediated by tumor-specific antibodies produced by B lymphocytes, 
mediate tumor killing by activation of the complement system as well as antibody-dependant 
cellular cytotoxicity (ADCC).30
4.  Cytotoxic  molecules secreted  by immune  cells;  e.g.  cytokines  like  TNF-α secreted  by 
macrophage; perforin and granzyme secreted by NK and T cells.43
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Figure  6:  Cellular  effectors  of  antitumor  immunity  and  some  cytokines  that  modulate  
antitumor activities. DC present tumor antigen to cytotoxic T cells (CD8+) which can kill  
tumor  cells  directly  by  releasing  cytotoxic  granules  (e.g.  perforin  and  granzyme).  The  
survival and persistence of CD8+ memory cells are regulated by CD4+ helper T cells. Both  
CD8+ and CD4+ secrete IFN-γ which up-regulate MHC class I and further sensitize cancer 
cells to CD8+ cells, promote recruitment of NK cells,  granulocytes and macrophages and 
interfere with angiogenesis. Dendritic cells can also activate IL-5 secreting CD4+ T-helper 2  
lymphocytes, which recruit eosinophils and stimulate the humoral immune system leading to  
antibody production by B-lymphocytes and plasma cells. Antibodies against tumor antigens  
can mediate antibody-mediated cell cytotoxicity (ADCC) by macrophages and NK cells.
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1.3.3. Cancers and immunosurveillance
Cancer can evade the immune system by several  escape mechanisms (reviewed by 
Marincola et al 44):
1.  Selective  outgrowth  of  antigen-negative  variants  during  tumor  progression.  Strongly 
immunogenic subclones may be eliminated.
2. Loss or reduced expression of HLA. Cytotoxic CD8+ and CD4+ T cells can recognize cell-
bound antigens only in association with HLA class I and II, respectively. However, this loss 
interrupts the inhibitory signals of NK cells and allowing their activation with lyses of target 
cells.
3. Lack of co-stimulatory molecules that is required for T cell sensitization. This may render 
T cells anergic or cause them to undergo apoptosis.
4.  Immunosuppression by tumor growth factors like TGF-β, which inhibit NK cells, NK-T 
cells and cytotoxic T cells, and IL-10 which can affect DCs function.29 
5.  The tumor-induced immune response includes T regulatory (Treg) and myeloid derived 
suppressor cells (MDSC), which suppress tumor immunity.
6.  Tumor cell  may inhibit  the T cell-receptor-induced surface expression of Fas-ligand on 
effector cells. Normally, Fas-ligand, cross links Fas receptor (CD95) on target cells, initiating 
caspase activation and leading to apoptosis.45
1.3.4. The pro-tumorigenic role of the immune system
The immune system has  a  paradoxical  role  during cancer  development.  Generally, 
chronic  activation  of  various  types  of  innate  immune  cells  might  contribute  to  tumor 
development/progression.  Whereas,  cells  of  the  adaptive  immune  system  carry  out 
surveillance and can eradicate various tumors.29, 46
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 In tissues, monocytes migrate to the site of injury guided by chemotactic factors, and 
once activated; tumor associated macrophages (TAMs) are the main source of growth factors 
and cytokines which facilitate tumor growth, angiogenesis, cell motility and invasion (Figure 
7).40 This antagonizes the anti-tumorigenic effect of macrophages and the net result may be 
pro-tumorigenic.41  In fact, an experimental study has demonstrated that interaction between 
lung cancer cells and macrophages promotes the invasiveness and matrix-degrading activity 
of  cancer  cells.47 Macrophages  are  polarized  into  M1  (antitumorigenic)  and  M2  (pro-
tumorigenic).  Differentiation of M1 TAMs is  induced by IFN-γ and TNF-α, whereas M2 
TAMs  activation  may  be  induced  by  signals  derived  from  Treg  cells  or  cancer  cells 
themselves (M-CSF, IL-10 and TGF-β).48    
Figure 7.  The role  of  macrophages,  M-CSF and CSF-1R in tumor growth and invasion.  
Macrophages stimulated by M-CSF can stimulate the growth of  cancer cells directly, as well  
as via stimulating angiogenesis. Angiogenesis and matrix degradation facilitate invasion and 
metastasis.
Similarly, CD4+ cells include, in addition to the T helper cells, Treg cells which are 
CD4+, CD25+ and Forkhead Box Protein P3-psitive (FOXP3+) cells and which suppress the 
effecter  functions  of  cytotoxic  T  cells.49 Furthermore,  a  subset  of  innate  immune  cells 
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(MDSC, which are CD11b+ cells) may accumulate in tumors and lymphoid tissue. MDSC are 
known to induce T lymphocyte dysfunction by direct cell-cell contact as well as production of 
immunosuppressive mediators.50   
Perhaps the most compelling clinical evidence for a causative link between chronic 
inflammation and cancer comes from studies reporting that inhibiting chronic inflammation in 
patients  with  pre-malignant  disease  has  preventive  effect.  Long-term  usage  of  anti-
inflammatory drugs (as COX2 inhibitors) significantly reduce the risk of some cancers.51
Finally, B  lymphocytes  were  found  to  be  required  for  establishing  chronic 
inflammatory states that promote de novo carcinogenesis via recruiting innate immune cells.52
1.3.5. Immunotherapy for Tumours
The facts that cancer is more common in immuno-compromized patients as well as the 
significantly better survival in cases with higher number of immune cells in the cancer tissues 
indicate that directed immunotherapy may be a way to battle against malignant cells.  This 
may be accomplished by:  
1.  Adoptive cellular therapy. Incubation of lymphocytes harvested from surgically resected 
tumor masses with IL-2 and IL-753 generates activated lymphocytes with potent antitumor 
activity in vitro (Figure 8).
 
Figure 8: Modification of CD8+ T cells with anti-tumor activity.
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2.  Cytokine therapy, e.g. IFN-γ is directly cytotoxic, it also activates NK cells and increase 
expression of HLA on tumor cells. 
3.  Antibody-based  therapy.  Monoclonal  antibodies  against  certain  B-cell  lymphoma  are 
already  in  use.  However,  antibodies  against  tumor-associated  antigens  have  not  proven 
efficacious in other types cancer.
4. Tumor vaccination utilizing DCs.54
5.  Disrupting  tumor-mediated  mechanisms  hindering  host  immunity could  be  a  novel 
approach to tumor immunotherapy. Treg depletion and blockade of differentiation improve 
endogenous anti-tumor immunity and the efficacy of active immunotherapy in animal models 
for cancer.49 Some chemotherapeutic agents, like sunitinib,  decreased the number of MDSC 
and Treg in tumor-bearing animals and reduced expression of IL-10, TGF-β, and Foxp3.55 
1.4. Tumor compartments
      
Until  recent  years,  the  principal  focus  in  cancer  research  has  mostly  been  the 
malignant  cell  itself.  Today,  it  is hypothesized that understanding the nature of the tumor 
environment  is  equally  important  for  future  cancer  therapy  as  understanding  the  cancer 
genetics.  Cancers  are  not  simply  collections  of  autonomous  malignant  cells,  but  also 
composed  of  multiple  cell  types  such  as  fibroblasts,  innate  and  adaptive  immune  cells, 
endothelial cells, and specialized mesenchymal cells. These different cell types in the stromal 
environment  can  be  recruited  by  malignant  cells  in  order  to  support  tumor  growth  and 
facilitate  metastatic  dissemination.   The  historical  lack  of  research  interest  in  the  tumor 
microenvironment  has  led to  a  significant  discrepancy between the vast  knowledge about 




Each tumor is composed of two compartments: 
1. The cancer cells (epithelial cells in case of carcinoma).
2.  Tumor  stroma:  A  peritumoral  specialized  connective  tissue  consists  of:  1)  The  non-
malignant  cells  of  the  tumor;  activated  fibroblasts,  specialized mesenchymal cell  types 
distinctive to each tissue environment, innate and adaptive immune cells, and the vasculature 
with  endothelial  cells  and  pericytes,  as  well  as  2)  the  extracellular  matrix  (ECM).  ECM 
consists of structural proteins (collagen,  elastin),  specialized proteins (fibrillin,  fibronectin, 
elastin) and proteoglycans.56
Tumor stroma plays a central role in tumor development, as it provides growth factors, 
blood supply, and exctracellular matrix and removes waste and dead cells. On the other hand, 
a variety of antitumor mechanisms acts through the tumor stroma.56 The expansion of the 
tumor stroma with an enhanced number of fibroblasts and increased deposition of ECM is 
termed tumor desmoplasia. Tumor stroma can be divided topographically into:
1. The stroma between tumor cells/clusters.
2. The stroma at the advancing edge of the tumor.
However,  in  most  cases  of  NSCLC  (especially  in  adenocarcinoma),  cancer  cells 
proliferate along the alveolar walls of the lung in the periphery of the tumor, and does not 
have stroma at the invasive margin39. Hence, such topographical stromal distinction was not 
done in our study.
1.4.2. The role of tumor stroma in the interaction between tumor and immune system
It  has  become  clear  that  analysing  the  tumor  microenvironment  is  of  crucial 
importance to better  understand cancer.56 Various cytokines  contribute to tumour rejection 
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mainly by their action on tumor stroma (e.g. by attacking angiogenesis, Figure. 9), whereas 
killing  mechanisms  mediated  by  molecules,  such  as  perforin  or  Fas  ligand,  act  on  the 
epithelial cells as well as the stroma.56 IL-4 secreted by CD4+ and CD8+ T cells helps in 
tumor  rejection  mainly  by  acting  on  the  tumor  associated  fibroblasts  in  the  tumor 
microenvironment  converting  them  to  a  phenotype  that  is  not  able  to  participate  in 
angiogenesis.57 
IFN-γ counteract  tumor-induced  angiogenesis  by  acting  on  the  endothelial  cells.58 
Finally, TNF-α suppress tumor growth by acting directly on endothelial cells, or indirectly by 
acting on non-bone-marrow derived cells inhibiting the release of pro-angiogenic factors.56 
Figure  9:  Different cytokines mediate their anti-tumour effect by attacking angiogenesis in  
the tumor stroma. IL4 acts mostly on tumor-associated fibroblasts, IL-10 on macrophages  
and TNFα and IFN-γ on endothelial cells (x=inhibition), modified from Blankenstein et al).56
1.5. Tissue microarray
Tissue microarrays (TMAs) may be used for large-scale investigation of the biologic 
and  prognostic  value  of  molecular  marker  families.  TMAs  allow  rapid  visualization  of 
molecular targets in hundreds of tissue specimens on a single slide, either at DNA, RNA or 
protein  level.59 The  technique  may  facilitate  rapid  translation  of  molecular  discoveries  to 
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clinical applications. However, it is a population-level research tool and is not intended for 
making clinical diagnosis for individual cases.60 Table 4 summarizes some of the advantages 
and disadvantages of TMA.
Table 4. Advantages and disadvantages with TMA technology.
Advantages Disadvantages
-  Time saving.  
- Cost effective.
-  Large number of cases can be analyzed.     
-  Consecutive sections can be taken. 
- Permits the whole staining procedure to be 
done as one experiment.
- Low representativity in heterogeneous 
tissue.
- Not suitable for diagnosis.
The history of TMAs is relatively short and one of the first premature multicore blocks 
was used in 1986, when Battifora described a method of embedding 100 or more different 
tissue  samples  in  a  normal  sized  paraffin  block.  During  the  last  decade  has  this  high-
throughput technique been commonly used.60 One of the first large scale TMA studies on 
NSCLC was published by Bremnes et al. in 2002.61 
TMAs, in contrast to  routine hematoxylin and eosin–stained sections, provide a far 
more efficient  workflow. With TMAs, the diagnostic skills  of the pathologist  occurs only 
once and up front avoiding the bias of post hoc analysis that can occur with conventional 
whole section analysis.62 Routine hematoxylin  and eosin–stained sections of tumors in the 
cohort are analyzed, and areas of tumor are circled by the pathologist (Figure 10). Thus, the 
pathologist‘s diagnostic skills are used in a prospective manner.62
However, TMAs are only as good as the cohorts from which they are created. Because 
TMA technology facilitates the development of large cohorts, researchers often use archival 
tissue  from greater  time  spans,  increasing  the  chance  that  variations  in  tissue  processing 
techniques  over  time can confound results.62 Although a common concern is  whether  the 
small  core  samples  used  in  TMA  analysis  give  meaningful  information  on  large  tumor 
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specimens,  up  to  95%  correlation  has  been  demonstrated  when  comparing  tumor  cell 
assessment in duplicate 0.6mm cores versus the whole slide.60 To our knowledge, we are the 
first using TMA technique to study variables such as immunological cell markers, in NSCLC 
tumor cells and tumor related stroma.
Figure 10:  The principle of tissue microarray. A: The hematoxylin-eosin slides from each  
tumor were studied and the desired areas marked. B: A tissue core biopsy was punched from 
the preselected region of neoplastic cells or tumor related stroma (0.6 mm in diameter). C:  
The  cylindrical  samples  were  extruded  directly  into  the  recipient  block  at  defined  array 
coordinates. D: Multiple 5-μm sections were cut and E: Immunohistochemical staining with  
selected antibodies to be studied. E.g. slide containing 202 cores, representing 47 patients. 
2.  AIMS OF THE STUDY
The aims of this study are:
1. To assess the role of different immune cell types in NSCLC and their relation to survival as 
well as to other clinicopathological variables. 
2. To study separately the meaning, if any, of the stromal and intraepithelial immune cells as 
different compartments of the same tumor.
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3. MATERIALS AND METHODS
3.1. Patients and tissue samples      
371 patients diagnosed with NSCLC pathological stage I-III at the University Hospital 
of  Northern  Norway and the  Nordland Central  Hospital  during  1990 through 2004 were 
considered for this study. Normal lung tissue was secured from normal paraffin embedded 
lung areas, but also from normal lung tissue obtained during autopsy. Demographic, clinical, 
treatment,  and  outcome  data  have  been  collected  from medical  records.  An  anonymised 
database was established. Survival data were updated in early 2009. 36 patients were excluded 
from the study due to: (i) Radiotherapy or chemotherapy prior to surgery (n = 10); (ii) Other 
malignancy within five years prior to NSCLC diagnosis (n = 13); (iii)  Adequate paraffin-
embedded fixed tissue blocks not available (n = 13).  Thus, 335 patients were included in this 
study (Figure 11). 
The median follow-up of survivors was 86 months (range 48-216). Two pathologists 
(Samer Al-Saad and Khalid Al-Shibli), blinded to any pathological or clinical information, 
reviewed all the cases; the diagnosis of carcinoma, histological type, vascular invasion and 
pathological stage were confirmed before including any case in the study. Nodal metastasis 
was assessed using the haematoxylin-eosin slides without using immunohistochemistry with 
cytokeratin  for  detecting  micrometastasis.  The  tumors  were  staged  according  to  the 
International  Union Against Cancer’s  TNM classification63,  stage IA and IB patients  were 
grouped  together  as  stage  I,  and  stage  IIA  and  IIB  patients  were  grouped  as  stage  II. 
Histological classification was done according to the World Health Organization guidelines.2 
The National  Data Inspection Board and The Regional  Committee for Research Ethics in 
Northern Norway approved this study. 
30
Figure 11: The patients included in the study.
3.2. Microarray construction
TMA were constructed by choosing the most representative paraffin block(s) for each 
case. Studies suggest that punching multiple 0.6mm cores from different regions captures the 
heterogeneity of the tumors more accurately than a single 2-4mm core.60 Hence, we chose to 
use four 0.6mm cores [two areas of viable invasive carcinoma tissue (neoplastic epithelium) 
and two from the surrounding tumor stroma] that were selected to be as representative as 
possible,  after  reviewing  all  the  original  sections  of  the  tumor  and  taking  the  fact  of 
heterogeneity  in  consideration.  In  addition,  all  the  surface  areas  of  the  four  cores  were 
assessed. The TMAs were obtained using a tissue-arraying instrument (Beecher Instruments, 
Silver Springs, MD), consisting of thin-walled stainless steel biopsy needles and stylets  to 
biopsy the donor block and transfer the needle content and empty it into the recipient block. 
We used 0.6 mm diameter stylet to sample two separate pre-defined neoplastic epithelial areas 
and two stromal areas. To include the entire 1340 plus the control cores, eight tissue array 
blocks  were  constructed.  Multiple  5-µm  sections  were  cut  with  a  Micron  microtome 
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(HM355S) and stained by specific antibodies for immunohistochemistry analyses. 
3.3. Immunohistochemistry
Sections  were de-parafinized with  xyline  and  re-hydrated  with  ethanol.  Antigen 
retrieval  was  performed  by placing  the specimens  in  0.01M citrate  buffer  at  PH 6.0 and 
exposed to two-repeated microwave heating of 10 minutes at 450W. The slides were then 
transferred to the Ventana Benchmark, XT automated slide stainer (Ventana Medical System, 
France).  Tissue  sections  were  incubated  with  primary  mouse  monoclonal  antibodies 
recognizing CD1a, CD3, CD4, CD8, CD20, CD34, CD56, CD68, CD117, CD138, M-CSF, 
and CSF-1R. The details of the antibodies and their incubation periods are shown in Table 5.
As secondary antibodies biotinylated goat anti-mouse IgG and mouse anti-rabbit IgM, 
both 200µg/ml, were used. The kit DAKO EnVision+ System-HRP (DAB) kit was used as 
endogen peroxidase blocking. The DAB kit was used to visualize the antigens by application 
of liquid diaminobenzidine and substrate-chromogen, yielding a brown reaction product at the 
site of the target antigen. Finally, all slides were counterstained with hematoxylin to visualize 
the nuclei. For each antibody, including negative staining controls, all staining was performed 
in a single experiment. As negative staining controls, the primary antibodies were replaced 
with the primary antibody diluents. 
3.4. Scoring of immunohistochemistry
By light microscopy, the tissue sections were scored for the degree of infiltration of 
different inflammatory cells. The percentages of these cells, compared to the total amount of 
nucleated cells in the epithelial and stromal compartments were assessed. The percentage of 
cells, and not a number, was used to make data more reproducible independent of the slide 













CD 1a Ventana JMP 457650 VMS 32
CD 3 Ventana PS1 504194 VMS 24
CD 4 Novacastra 1F6 116057 1/5 20
CD 8 Ventana 1A5 492779 VMS 32
CD 20 Ventana L26 4198946 VMS 16
CD 34 Ventana QBEnd/10 508686 VMS 32
CD 56 Ventana 123C3.D5 21036 VMS 16
CD 68 Ventana KP-1 508662 VMS 16
CD117 Ventana Anti-C-kit (9.7) 506649 VMS 32
CD138 Ventana B-A38 20057 VMS 32
CSF-1R Santa Cruz* H-300 K0404 1:25 16
M-CSF Santa Cruz* H-300 K0304 1:5 28
Table 5: The antibodies used in the study.
*Santa Cruz Biotechnology.
**Ventana antibodies are ready diluted from the manufacturer.
nucleated cells in the epithelial compartment or >25% in the stromal compartment,  and low 
otherwise. Both CD20+ and CD1a+ cells were scored as low if absent or representing <1% of 
the nucleated cells and high otherwise in both epithelial and stromal compartments. DCs were 
identified by their brown membranous immunoreactivity as well as their cytoplasmic flame-
like extensions. The same scoring (<1% of the nucleated cells) was applied to intraepithelial 
CD68+ cells, whereas CD68+ cells in the stroma were more abundant and scored as low if 
they represented <25% of total nucleated cells and high otherwise. Both CD56+ and CD117+ 
cells  were  present  in  the  epithelial  compartment  in  only  seven  cases  and  in  the  stromal 
compartment  in  few  cases,  and  when  present  they  were  very  sparse  and  their  highest 
concentration did not exceed 1%. Hence, they were scored as absent or present in both the 
stromal and epithelial cores. CD3+ cells were abundant in the stroma and were scored as high 
if they represented >50% of nucleated cells in the stroma, whereas <1% in the epithelium was 
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scored as low and high otherwise. For CD8+ cells the cut-off point was ≤5% and ≤50% for 
epithelial and stromal components, respectively.
CD138 is known to stain epithelial cells themselves and the staining intensity in the 
epithelial  compartment was scored as 0 = negative; 1 = weak; 2 = intermediate;  and 3 = 
strong. A similar scoring was used for epithelial M-CSF and CSF-1R. High expression in 
tumor epithelial cells was defined as score >1.0 for CD138 and ≥1.5 for both M-CSF and 
CSF-1R. Stromal M-CSF and CSF-1R expressions were calculated by adding intensity score 
(as above) to density score [scored by measuring the ratio of positive cells compared to the 
surface area of the extracellular matrix, and was categorized accordingly as: 1 = low density 
(<25% cell/matrix ratio); 2 = intermediate density (25-50%) and 3 = high density (>50%)] 
before categorizing into low and high expression. High expression in the stroma was defined 
as >3.5 and >3 for M-CSF and CSF-1R, respectively.
The  interstitial  tissue  of  the  non-neoplastic  normal  controls  showed  few  (1-5%) 
CD68+ CD3+, CD4+ and CD8+ cells; and very sparse (0-1%) CD117+, CD138+, CD56+ and 
CD1a+  cells.  There  was  no  significant  infiltration  of  the  normal  bronchial  columnar 
epithelium  by  any  type  inflammatory  cells.  The  bronchial  columnar  epithelium  showed 
moderate membranous and cytoplasmic positivity for CD138. Almost all pneumocytes in the 
control sections were weakly positive for M-CSF, whereas 30% were weakly positive for 
CSF-1R. Almost all alveolar macrophages showed moderate to severe positive staining for 
both M-CSF and CSF-1R. 
 MVD was assessed using CD34 immunohistochemistry. Any stained endothelial cell 
or endothelial cell cluster was considered as a single countable microvessel.  Stromal MVD 
was scored as 0, negative; 1, 1-10 vessels per core; 2, 11-20 vessel per core; 3, >20 vessel per 
core.  A mean score for duplicate cores from each patient was calculated, and high stromal 
MVD was defined as a mean score ≥3.64 
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All samples were anonymized and independently scored by two pathologists (Samer 
Al-Saad and Khalid Al-Shibli). In case of disagreement, the slides were re-examined and the 
observers reached a consensus. When assessing one marker in a given core, both observers 
were blinded regarding the scores of other markers as well as to the patient’s outcome. The 
inter-observer  scoring  agreement  between  the  two  pathologists  was  tested  on  the  current 
material  in a previous report.64 The mean correlation coefficient (r) was 0.95 (range 0.93-
0.98). 
3.4.1 Cut-off points
Variation in methods including differences in tissue preparation, antigen retrieval, and 
assessment of positive staining makes it difficult to standardize cut-off values. Many studies 
use the median as cut-off value, but the obvious disadvantage with this approach is missing 
biological interesting mechanisms. For instance, this may be the case where only the minority 
or the majority of the patients had a high expression level linked to a certain biological effect. 
In our binary cut-off points for the biomarkers, the cut-off was determined for each variable 
so that  the two resulting subgroups were the most  different  according  to  disease specific 
survival (DSS). The main drawback with this approach is the danger of false positive results, 
and especially  borderline  significant  results  in  the  analyses  must  be interpreted  carefully. 
Arbitrary cut-off points at 1%, 5%, 25%, or 50% for each cell/compartment according to the 
degree of cell densities were used, as these percentages are easy to follow and reproduce in 
daily practice.
3.4.2. Controls and limitations
Both  reagent  and  tissue  controls  were  used.  Of  all  components  used  for 
immunohistochemistry, the primary antibody is the most critical. Occasionally other reagents 
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may need to be replaced. As reagent control, diluent without primary antibody was used.
The limitation of this study is that  a single marker identifies each immune cell type. 
CD68 is not specific for macrophages and has been found in CD1a-positive DCs as well.65 
Although most tumor-infiltrating CD8+ T cells are cytotoxic T cells, some CD8+ T cells are 
regulatory T cells in cancers including NSCLC.66 In addition to different T cells, CD4 can be 
expressed by immature DCs but decrease during maturation.67 Therefore, it is possible that 
some of the cells identified by used markers are not the named immune cells.
3.5. Statistical analysis
All statistical analyses were performed using the statistical package SPSS.  The Chi-
square test and Fishers Exact test were used to examine the association between the density of 
the inflammatory cell infiltrates and clinicopathological parameters. Univariate analysis was 
performed by using the Kaplan-Meier method, and statistical significances between survival 
curves were assessed by the log-rank test. DSS was determined from the date of surgery to the 
time of lung cancer death. To assess the independent value of different pre-treatment variables 
on survival, multivariate analysis was carried out using the Cox proportional hazards model. 
Only variables with a significant P value from the univariate analysis were entered into the 
Cox regression analysis. Probability for stepwise entry and removal was set at 0.05 and 0.10, 
respectively. The significance level was set at P < 0.05.
4. MAIN RESULTS
The patients’ age ranged between 28 and 85 years (median was 67 years), and 75% 
were  males.  The  NSCLC  tumors  comprised  191  squamous  cell  carcinomas,  95 
adenocarcinomas,  31 large-cell  carcinomas and 18 BACs.  Due to nodal metastasis and/or 
non-radical surgical margins, 59 (18%) patients received postoperative radiotherapy.  There 
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were  232  lymph  node  negative  cases  (N0),  and  103  cases  with  regional  lymph  node 
metastases (76 N1, 27 N2). 
Performance  status,  pathological  stage,  T-status,  N-status,  differentiation,  surgical 
procedure  used,  vascular  infiltration,  and  postoperative  radiotherapy  were  all  significant 
indicators for disease free survival in univariate analyses. Tumor stage (P = 0.002) and nodal 
status (P < 0.0001) were the strongest prognostic factors. 
Infiltration of different  types inflammatory cells were seen in both the intraepithelial 
and stromal compartments. T and B-lymphocytes were the most common inflammatory cell 
types, followed by macrophages. Whereas NK cells (CD56+) and mast cells (CD117+) were 
the rarest. Tumor infiltrating lymphocytes were observed in both the epithelial and stromal 
compartments, and they were generally more abundant in the stroma.
Figure 12: Kaplan-Meier  survival  curves  with  microscopic  pictures  comparing  high  and 
low CD4+ cells in the stromal (A) and epithelial (B) compartments.  
4.1. Paper I
In this study, the aim was to assess the significance of CD4+ and CD8+ T cells, as 
well  as  B-lymphocytes  (CD20+)  in  NSCLC intraepithelial  and  stromal  compartments.  In 
univariate  analyses,  increasing numbers of stromal  CD4+ (P < 0.001, Figure 12), stromal 
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CD20+  (P  <  0.001)  and  stromal  CD8+  (P  =  0.002,  Figure  13)  lymphocytes  correlated 
significantly with an improved DSS. The main findings in this study were related to the tumor 
stromal compartment, where a high number of stromal CD4+ (P = 0.002) and stromal CD8+ 
(P  =  0.043)  lymphocytes  were  independent  prognostic  factors  for  DSS.  Stromal  B-
lymphocytes had a positive prognostic effect only in univariate analysis. Furthermore, a high 
level of stromal CD8+ lymphocytes was associated with a lower incidence of angiolymphatic 
invasion (P = 0.032).
 Figure 13: Kaplan-Meier survival curves with microscopic pictures comparing high and   
 low CD8+ cells in the stromal (A) and epithelial (B) compartments.  
Epithelial  lymphocytes  showed  a  significant  antitumor  effect,  but  only  in  the 
univariate analyses. A large number of epithelial CD8+ lymphocytes had a significantly better 
DSS than those with low CD8+ cell numbers (P = 0.023). This was observed, however, only 
in patients  without lymph node metastasis (N0) (P = 0.018), whereas patients  with lymph 
node metastasis (N1 and N2) did not showed a significant tendency for better DSS (N1 P = 
0.583, N2 P = 0.760). Epithelial  CD20+ lymphocytes  showed a similar  significance (P = 
0.023) that was limited to squamous carcinoma (P = 0.030). Epithelial CD4+ cells showed no 
significant  correlation with DSS, and analysis  of the cases in subgroups failed to show a 
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significant prognostic association.    
4.2. Paper 2
In this  paper,  we assessed the role  of the innate  immune system cells  in  NSCLC. 
Tumor  infiltrating  CD56+ cells  were very sparse in  both  compartments.  The 37 cases  in 
which CD56+ cells were present in the stroma, showed a significantly better DSS than those 
in  which  NK  cells  were  absent  (P =  0.014).  No  significant  association  with  other 
clinicopathological  variables  was  noted.  For  the epithelial  compartment,  only seven cases 
have CD56+ cells, an inadequate number for statistical analysis. Macrophages (CD68+) were 
observed in the epithelial and stromal compartments, and they were generally more abundant 
in the stroma. In neither compartment did the CD68+ cells show any significant correlation 
with DSS (epithelial, P = 0.13; stromal, P = 0.11, Figure 14). 
Figure 14 : Macrophages stained with CD68 in both tissue compartments (A, x400). Kaplan-
Meier survival curve comparing high and low stromal CD68+ cell count (B).
Regarding CD1a+ cells, they were more abundant in the tumor stroma of females than 
males (high expression; 33% males and 56% females, P < 0.001), and in well differentiated 
than in less differentiated tumors (high expression; 31%, 37% and 60% for low, moderate and 
highly  differentiated  tumors,  respectively,  P  = 0.001).  The  group of  patients  with  a  high 
stromal  CD1a+ cell  count had a significantly better  DSS than those with a low one (P = 
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0.011). This was not seen for epithelial CD1a (P = 0.65). Furthermore, patients without lymph 
node metastases  showed a significantly higher stromal  CD1a count than those with nodal 
metastasis (high expression; 45% for N0, 25% for N1 and 19% for N2, P = 0.001). No such 
associations were noted for epithelial CD1a+ cells.
M-CSF and CSF-1R showed high staining score in the epithelium in 63% and 42% of 
the cases, respectively (Figure 15). No significant association with DSS was noted (P = 0.37 
and 0.83, respectively). The same applies for stromal M-CSF and CSF-1R (P = 0.82 and 0.71, 
respectively). Neither did subgroup analysis show any significant association with DSS.
In multivariate  analyses, high number of stromal  CD56+ cells  was an independent 
prognostic factors for DSS (HR 2.3, CI 1.1-5.0, P = 0.031). 
Figure 15. Epithelial CSF-1R low (A), high (B); M-CSF low (C) and high score (D). X200.
4.3. Paper 3
Tumor infiltrating CD3+ cells  were seen in both compartments.  Patients  with high 
stromal CD3+ cells had a significantly better DSS than those with a low count (P = 0.001) 
(Figure 16). No significant association with other clinicopathological variables was noted. For 
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the epithelial  compartment,  high CD3+ cells  was also associated  with a better  DSS (P = 
0.004).
 
Figure 16: Kaplan-Meier survival curve (A) with microscopic pictures comparing high (B)  
and low (C) CD3+ cells in the stromal compartment, x400.  
CD138+  cells  were  more  abundant  in  the  stroma  than  in  the  epithelium.  In  the 
epithelial compartment CD138+ cells showed no significant correlation with DSS (P = 0.85). 
Sub-analyses according to histological type, gender, stage and differentiation did not reveal 
significant prognostic associations. Similarly, high stromal CD138+ cells was associated with 
a tendency for a better DSS but did not reach significance (P = 0.12). However sub-analyses 
of CD138+ cells according to gender revealed a significant better DSS in males (P = 0.029), 
and sub-analyses according to T and N status showed a positive prognostic effect in advanced 
stage (T3, P = 0.046; N2, P = 0.029 and stage III, P = 0.034). 
With respect to cancer epithelial cell staining, CD138 showed a significantly higher 
positivity in squamous cell carcinoma compared to other histological types (squamous cell 
carcinoma,  82%;  adenocarcinoma,  49%;  bronchioalveolar  carcinoma,  50%;  large  cell 
anaplastic carcinoma, 63%; P<0.001). However, CD138 was not associated with DSS in any 
histological type. 
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CD117+ cells in the stroma showed no significant association with DSS, or with any 
of the clinicopathological  variables  studied.  There was a weak correlation between MVD, 
assessed by CD34 (Figure 17) and CD117+ cells (R=0.226, P = 0.001). 
Figure 17. Stromal staining with CD34 showing high (A) and low (B) MVD score, x400
In  the  multivariate  analysis  a  limited  number  of  stromal  CD3+  cells  was  an 
independent negative prognostic factor for DSS (HR 1.925, CI 1.21-3.04, P = 0.005). 
5. DISCUSSION
Approximately one-third of NSCLC patients are diagnosed with early disease and for 
those  patients  surgery  is  the  most  effective  treatment  with  an  intent-to-cure.  Following 
surgery, distant recurrence is the most common form of relapse and eventual cause of death as 
demonstrated by Subotic et al68 in their prospective study in which they found locoregional, 
distant or both types of relapse in 26%, 70% and 4% patients respectively. Hence, there is a 
need  for  new  prognostic  indicators  and  therapeutic  agents.  Our  study  suggests  that 
intratumoral lymphocytes modify tumor stroma or tumor epithelium (or both) in ways that 
attenuate tumor progression. Most of the beneficial effect of TILs was related to the stromal 
compartment,  where  CD8+,  CD4+,  CD3+  and  CD56+  cells  were  independent  positive 
prognostic  factors  in  our  NSCLC  cohort.  This  highlights  the  importance  of  the  tumor 
microenvironment, and may point to the fact that using simple immunological parameters on 
42
the routine histological materials  may single out those individuals who are more likely to 
benefit from e.g. adjuvant treatment. To our knowledge, this project is the first to analyse a 
wide spectrum of immune cells in both tumor compartments of a large number of resected 
NSCLC tumors.
Two  important  questions  must  be  addressed  prior  to  introduction  of  a  prognostic 
marker in clinical practice: 1) Does the marker have an effect independent of the TNM stage? 
and 2) is there a reliable measurement method available for this factor in routine practice?15 
The  investigated  immune  components  appear  to  satisfy  both  questions.  In  our  research 
subjects, the primary tumors were surgically removed. The prognostic impact associated with 
the different lymphocytes may indicate an ability by systemic effectors to recognize and kill 
circulating cancer cells in the peripheral blood, pleura, bone marrow and lymph nodes, which 
may lead to elimination of cancer cells or to a state of equilibrium. 
5.1. Chronic inflammation and cancer 
Near 150 years ago, Virchow postulated that inflammation is a predisposing factor for 
tumorigenesis. This hypothesis was based on his observation that cancerous tissue often arose 
at sites of chronic inflammation,  and that inflammatory cells  were present in the resected 
tumors.69 In contrast, Burnet31 proposed in 1970 the hypothesis that the immune system has 
the ability to spontaneously identify and eliminate cancer cells, and will consequently protect 
against  tumor  development;  the  concept  of  immunological  surveillance.  When  tissue 
homeostasis is chronically perturbed, interactions between innate and adaptive immune cells 
can  be  disturbed.  While  innate  immune  cells  form the  first  line  of  immune  defence  and 
regulate activation of adaptive immune responses, this role can be reversed during chronic 
inflammation.29 In the latter situation, adaptive immune responses can cause T lymphocyte 
dysfunction  instead  of  activation.70 The inability  to  properly engage  and/or  disengage the 
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innate or adaptive immune system can result in excessive tissue remodelling, loss of tissue 
architecture  due  to  destruction,  protein  and  DNA alterations  due  to  oxidative  stress  and 
increased risk of cancer development.29 
So, host immunity protect against cancer. But according to recent research, subsets of 
chronically activated immune cells may promote tumor growth and/or facilitate survival of 
cancer  cells.29  This  raises  several  questions  about  the  underlying  mechanisms  for  these 
tumor-promoting effects, and whether they can be blocked while maintaining or enhancing 
the antitumor immune responses.
The  connection  between  inflammation  and  cancer  were  characterized  along  two 
pathways  by  Mantovani  et  al71 (Figure  18):  1)  an  extrinsic  pathway,  driven  by  chronic 
inflammatory/infectious  conditions  which  increase  cancer  risk (e.g.,  chronic  inflammatory 
disease) and 2) an intrinsic  pathway,  driven by genetic  alterations  (oncogenes)  that  cause 
inflammation  and subsequently  neoplasia.  These  two pathways  converge,  resulting  in  the 
activation of transcription factors, mainly nuclear factor-κB (NF-κB), signal transducer and 
activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF1α) in tumor cells. 
These factors again coordinate the production of inflammatory mediators as cytokines and 
chemokines,  which  recruit  and  activate  various  leukocytes,  mainly  cells  of  the 
myelomonocytic  lineage.  The  cytokines  activate  the  same  key  transcription  factors  in 
inflammatory cells as well as in other stromal cells and cancer cells, resulting in an elevated 
production of inflammatory mediators and establishment of a cancer-related inflammation.
5.2. Different  immune cells and NSCLC
5.2.1.  CD4+ cells and NSCLC
CD4 is a nonpolymorphous glycoprotein belonging to immunoglobulin superfamily. It 
is a marker of T helper lymphocytes, which play a crucial role in initiating and maintaining 
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Figure 18. Pathways connecting inflammation and cancer. Chronic inflammatory or
infectious conditions, enhancing the risk for cancer development, constitutes the extrinsic
pathway. The intrinsic pathway is activated by genetic events (oncogene mutation,
inactivation of suppressor genes, amplifications) which cause neoplasia. The pathways
merge and results in the activation of transcription factors. Adapted from Mantovani et al71.
Abbreviations: NF-κB, Nuclear factor-κB; STAT3, signal transducer and activator of
transcription 3; HIF1α, hypoxia-inducible factor 1α.
anticancer  immune  response.  In  the  absence  of  CD4+  cells,  cytotoxic lymphocytes  can 
become lethargic or even be deleted. In fact, CD4+ helper cells are needed to imprint CD8+ 
cells with the ability to develop into long lasting memory cells. In addition, CD4+ cells can 
recruit  other  immune  cells  and  can  directly  kill  tumor  cells.  Our  results  highlight  the 
independent beneficial effects of CD4+ T cells in NSCLC, mediated via the tumor stroma. 
Similar  conclusion  has  been  found  in  other  studies  involving  NSCLC39 as  well  as  other 
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cancers, including lymphomas.72 The favorable prognostic effect was augmented in the group 
of patients having a simultaneously high CD8+ cells, confirming the co-operation between 
CD4+ and CD8+ cells and the most optimal antitumor effect in case of concurrent high CD4+ 
and CD8+ cells as noted earlier by Hiraoka.et al.73 However, CD4+ cells are heterogeneous 
and in addition  to  the effector  cells,  regulatory cells  also found. The regulatory cells  are 
CD4+, CD25+ and FOXP3+ and may mediate immune tolerance and eradication of T effector 
cells. Our results show that the net effect of CD4+ cells is a beneficial one in NSCLC. In fact, 
even Treg cells were found, paradoxically, to be associated with a better loco-regional control 
in  head  and  neck  carcinoma74;  whereas,  high  ratio  of  Treg  over  Th2  cells  resulted  in  a 
significantly shortened disease-free survival in Hodgkin lymphoma.75
5.2.2. CD8+ cells and NSCLC
CD8 is  a cell  surface glycoprotein and a member of immunoglobulin  superfamily; 
located  at  2p12. It  seems that  despite  HLA-haplotype  loss,  a vigorous antitumor  immune 
response mediated by CD8+ cells  can be present in NSCLC.45 The presence of numerous 
CD8+ cells has been associated with epithelial damage resulting in the clinical manifestations 
of diseases like lymphocytic colitis and Celiac disease. A similar CD8+ cell kill is beneficial 
in  association  with  different  types  of  malignant  tumors34,  76,  77,  including  NSCLC.45.  It  is 
thought that tumor rejection by CD8+ T-cell effectors is primarily mediated by direct killing 
preceded by IFN-γ mediated inhibition of tumor-induced angiogenesis.58 Anyway, it seems 
that the beneficial effect of CD8+ and CD4+ cells is mediated primarily via the tumor stroma, 
corroborating  the  findings  by  Fassnacht  et  al78 who  targeted  tumor  stromal  antigens  to 
stimulate  cytotoxic  CD8+  responses  and  reduce  the  ability  of  tumors  to  evade  immune 
elimination.       
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5.2.3. CD20+ cells and NSCLC
CD20 is a phosphoprotein initially expressed on B cells after CD19/CD10 expression 
and before CD21/CD22 and surface immunoglobulin expression; retained on mature B cells 
until plasma cell development. 
We postulate that patients’ humoral immunity may play a role in long-term survival. 
This notion is based on the observed survival in patients who were found to have high B-
lymphocytes in the stroma, although this was not an independent prognostic factor. There are 
many possible  mechanisms  that  may explain  why the  presence  of  peritumoral  B cells  is 
involved with prolonged survival.  Possibly,  this immune response helps to locally contain 
some  tumors,  thereby  reducing  the  true  incidence  of  occult  micrometastases.79 If  occult 
metastases  are  present,  such  immunity  might  prolong  survival  by  limiting  further  tumor 
dissemination. In addition, the presence of B cells may mirror the host’s overall immunity. 
Those able to mount an immune response may preselectively be in better overall condition. 
Finally,  antibodies produced by B cells are important for the killing of tumor cells by NK 
cells and other inflammatory cells through ADCC. 
5.2.4. CD1a+ cells and NSCLC
DCs are the most potent antigen presenting cells, and represent a heterogeneous group 
of cells that express different markers. We used CD1a which is a common DC marker in the 
daily  routine.  CD1a is  a  transmembrane  glycoprotein,  which is  structurally  related  to  the 
MHC proteins and form heterodimers with beta-2-microglobulin. Although mostly expressed 
on  immature  DCs,  mature  DCs  also  express  this  marker.80,  81 Other  DC markers  are  not 
specific:  The  CD83 molecule  has  also been found in  other  cells  including B cells;  while 
CD208, originally considered a specific marker of mature DCs, is also expressed in normal 
lung and lung adenocarcinoma epithelial  cells.82,  83 In our cases CD1a does not show any 
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staining in the tumor epithelial  cells.  Hence, CD1a appears to be a reasonable marker for 
visualizing DCs. 
The positive prognostic impact of stromal DCs in our cohort is consistent with several 
previous  studies  reporting  of  their  prognostic  significance  in  different  neoplasms,  as 
colorectal84, hepatocellular85, breast carcinoma80 as well as NSCLC.86 In addition to their key 
function as antigen presenting cells, DCs may themselves contribute to cancer cell killing by 
direct  cytotoxicity  or  cytokine  production  (so-called  killer  DCs  and  IFN-producing  killer 
DCs).86-88 Many tumors, however, inhibit the maturation and function of DCs by secreting 
mediators  like IL6 and VEGF.  In this  context,  anti-VEGF treatment  may be a  promising 
therapy  capable  of  restoring  DC  function  in  addition  to  suppressing  angiogenesis.86 In 
addition,  many  tumors  (like  colon  carcinoma)  secret  COX2  which  leads  to  increased 
prostaglandin which acts on EP2 and 4 receptors on DC cells affecting their function (Figure 
19).84 Finally,  following culture with human lung carcinoma cells, DCs showed decreased 
production of TNF-α and IL-12, and were converted to TGF-β-producing DCs, which were 
poor at eliciting the activation of naive CD4+ T cells and sustaining their proliferation and 
differentiation into Th1, IFN-γ + effector cells.89
Figure 19: Cancer can evade the anti-tumorigenic effect  of DC. Cancer epithelial  and/or 
stromal  cells  can  produce  IL-10,  IL-6,  VEGF  and  prostaglandins  that  can  inhibit  DCs 
maturation and function (e.g. decrease IL-12 and TNF-α, and increase TGF-β production),  
resulting in an abnormal CD4+ helper cells differentiation.
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5.2.5. CD56+ cells and NSCLC
CD56 is the most commonly used surface marker to identify NK cells. It presents on 
near all NK cells as well as T memory cells and neuronal tissue. NK cells kill malignant cells 
in two ways: 1) Granule mediated cytotoxicity (perforin, granzyme and TNF-related granules) 
and 2) secreting cytokines (e.g. IFN-γ, IL5, M-CSF, GM-CSF) and chemokines (e.g. CCL1 
and CCL3)42. NK cell activation is regulated by a balance of signals that are generated from 
activating and inhibitory receptors. Every NK cell expresses at least one inhibitory receptor 
that  recognizes  a  self-MHC class  I  molecule.  So,  normal  cells  that  express  MHC class  I 
molecules are protected from self-NK cells, but transformed or infected cells that have down-
regulated  MHC  class  I  expression  are  attacked.90 Although  NK cells  in  our  study  were 
relatively sparse, their presence in the stroma was an independent prognostic marker for a 
better  DSS.  A  similar  finding  has  previously  been  noted  in  a  study  on  squamous  cell 
carcinoma91 and adenocarcinoma92 of the lung, as well as in other malignancies as colorectal93 
and gastric carcinomas.94 Moreover, the presence of a higher number of NK cells in normal 
regional lymph nodes was associated with a lower incidence of disease recurrence in gastric 
carcinoma.95 The fact that there is a high level of loss of MHC class I in NSCLC96, increases 
the significance of NK cells  in tumor immunity,  as loss of  MHC class I will  remove the 
inhibitory  effect  of  NK cells  and  stimulate  their  tumor  killing  capability.  Carrega  et  al97 
assessed NK cells in NSCLC and found that their cytolytic activity is lower than that of their 
peripheral  blood  counterparts,  whereas  no  difference  was  observed  regarding  cytokine 
production. They also found that NK cells were localized in the stroma.     
5.2.6. CD68+ cells, MCSF and CSF-1R in NSCLC
The role of M-CSF, a major regulator of the mononuclear phagocytic lineage, and its 
receptor CSF-1R in tumor progression has been extensively studied in several types of cancer. 
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Expression of these have correlated with poor prognosis especially in breast98, endometrial99 
and  prostate100 carcinomas.  Although CSF produced  by  lung  cancer  cells  might  promote 
tumor  progression  by  autocrine  and  paracrine  mechanisms  through  stimulating  enhanced 
production of extracellular matrix degrading proteinases by the tumor cells or by prolonging 
tumor cell survival101, the role of M-CSF and its receptor at tissue level is not well studied in 
NSCLC. M-CSF secreted from the tumor acts to divert antitumor macrophage responses and 
suppresses the differentiation of mature tumor-antigen-presenting DCs.98 Although M-CSF 
and its receptor showed high epithelial staining in 63% and 42% of our NSCLC cases, there 
was no significant association with survival. 
The  macrophage  constitute  a  major  component  of  the  inflammatory  infiltrate  in 
tumors.69 TAMs may  enhance  cancer  progression  through activation  to  M2 macrophages 
which  facilitate  matrix  remodelling,  angiogenesis  and  stimulation  of  tumour  growth  and 
motility  through  the  synthesis  of  growth  and  chemotactic  factors.48 Interestingly,  these 
functions  are  also normally found in  wound healing  and inflammation.  This  supports  the 
notion  that  tumors  are  'wounds  that  never  heal'  and  suggests  that  chronic  inflammation 
through persistent infection or by other means might be an important co-factor in the genesis 
and  promotion  of  malignancy.102 Meanwhile,  macrophages  have  also  an  anti-tumorigenic 
action mediated  by  classically activated M1 macrophages  that  produce effector  molecules 
such as reactive oxygen intermediates, reactive nitrogen intermediates, and TNF-α, to limit 
tumor growth.48 Heterogeneity of macrophages may account for part of the controversies with 
respect to the prognostic role of TAMs, and may explain the lack of significant survival effect 
in our study cohort.
5.2.7. CD3+ cells and NSCLC
In paper 1, we demonstrated the  independent  prognostic significance of CD4+ and 
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CD8+ cells in NSCLC. CD3 stains both these cell groups and, in addition, a subset of NK 
cells  (NK-T  cells)  that  are  CD3+  and  CD56+,  as  well  as  CD4-,  CD8-  T  cells  (with 
gamma/delta T cell receptor). The aim in assessing CD3+ cells was to confirm the prognostic 
effect  of  CD4+  and  CD8+ cells,  and  to  see  if  such  an  effect  is  maintained  taking  into 
consideration  other  cell  types  represented  by  the  pan  T  marker  CD3.  NK-T  cells  kill 
malignant  cells  without  the  need  for  previous  sensitization  and  in  an  MHC-unrestricted 
manner29.  High numbers  of  CD3+ cells  have been  associated  with increased  apoptosis  in 
NSCLC patients.103 Kataki et al41 concluded that the CD3+ cells in lung carcinoma result from 
recruitment  of  circulating  precursors  rather  than  from  local  replication,  which  may  be 
important  when considering  the possible  therapeutic  relevance  of  these cells.  Our  results, 
specifically the independent significance of immune cells in the stromal component, highlight 
the significance of the stromal compartment in cancer survival and progression. T cells utilize 
cytokines  to inhibit  tumor stroma formation and cytotoxic  molecules to kill  epithelial  and 
stromal cells that cross-present antigens.56 Any possibilities to modulate stromal lymphocyte 
cytotoxicity in the close vicinity of cancer cells would be of substantial clinical interest. 
5.2.8. CD117+ cells and NSCLC
CD117 is the receptor for kit protein, a 145 kD tyrosine kinase growth factor receptor 
protein  important  for  development  and survival  of  mast  cells,  haematopoietic  stem cells, 
melanocytes, germ cells and interstitial cells of Cajal. Apart from mast cells, the other above-
mentioned cell types are unlikely to be observed in NSCLC tissue. As a consequence, we used 
CD117 as a marker of mast cells in our cohort. We observed only sparse number of mast 
cells, solely in the stromal compartments.
Mast  cells  are  found  in  various  solid  tumors  and  can  enhance  angiogenesis  via 
multiple interacting factors104. In a previous NSCLC study, the density of mast cells correlated 
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with MVD, but not survival105. However, mast cells can express natural cytotoxicity against 
tumor cells and produce cytokines with anti-tumor activity, like TNF-α. This can explain the 
finding by Tomita et al106 where a higher density of mast cells correlated with improved DSS 
in  90  adenocarcinoma  patients.  In  a  study on  gastric  carcinoma,  Yano  et  al107 found,  in 
contrast, accumulation of mast cells in the stroma to correlate with increased vascularization, 
angiolymphatic invasion, metastases, and poor DSS. For this reason, mast cells have been 
regarded  as  a  double-edged  sword  in  cancer  immunity.  This  may  explain  the  lack  of 
prognostic impact by mast cells in our study cohort. Corroborating our data, two previous 
studies40,  108 reported a neutral prognostic effect of mast cell density in stage I-IV NSCLC 
tumors.  The lack of a strong association between MVD and mast cell density in our cohort 
may be related to the different mast cell phenotypes, as only the tryptase+ mast cell is closely 
associated with increased angiogenesis109. CD117 do not differentiate between these different 
types of mast cells. 
Previous studies  have  reported  a  negative  prognostic  impact  of  high  MVD  in 
NSCLC.110 To our knowledge, this is the first TMA study to evaluate the effect of MVD in 
NSCLC. There was no prognostic impact of MVD assessed in tumor or stromal cores. This 
may be explained by the TMA technique’s unsuitability for evaluating MVD.64 
      
5.2.9. CD138+ cells and NSCLC
CD138+  is  a  member  of  the  syndecan  family  which  regulates  cell-cell  and  cell-
extracellular matrix adhesion, cell migration and growth factor activity. It is expressed mainly 
in  plasma  cells,  normal  epithelial  cells,  transiently  in  condensing  mesenchyme  during 
embryogenesis  as  well  as  some  stromal  cells.111 CD138  stains  epithelial,  in  particular 
squamous  cells.  Loss  of  CD138  expression  in  epithelial  cells  is  associated  with  tumor 
aggressiveness  in  head  and  neck  carcinoma;112 and  reduced  CD138  expression  has  been 
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observed in invasive squamous cell carcinoma when compared to carcinoma in situ.113 Shah et 
al114 demonstrated reduced survival with loss of epithelial CD138 expression in 63 NSCLC 
cases. No such association could be demonstrated in our cohort, in consistency with the study 
by Toyoshima et al115 on 97 NSCLC cases. 
      CD138+  cells  infiltrating  both  the  stromal  and  epithelial  compartments  were  also 
analyzed,  neither  tumor  compartments  had  significant  survival  effect,  though  the  stromal 
density showed a trend for a better prognosis. In a study assessing CD79a+ cells (stains B 
lymphocytes  as well  as  plasma cells)  no significant  prognostic  effect  was noted in  either 
tumor  compartment116.  CD138  stains,  in  addition  to  plasma  cells,  some  stromal  cells 
(fibroblast), which enhance tumor angiogenesis and hence tumor growth and progression.111 
However,  in  stage  III  NSCLC survival  was  significantly  better  in  patients  with  a  higher 
number  of  stromal  CD138+ cells.  This  may  indicates  a  crucial  role  of  plasma  cells  and 
antibody mediated immunity in advanced disease, and needs to be re-examined by a larger 
series of stage III as well as stage IV disease. 
6. CONCLUSION
The results of our study suggest that:
1.  NSCLC patients respond towards their tumors by cellular immunity and in patients with 
stage I-IIIa NSCLC, different types immune cells infiltrate the tumor epithelial and stromal 
compartments. 
2.  As surgically treated  patients  with similar  histology and stage can have a significantly 
different prognosis, prognostic effects can be identified by assessing the status of the tumor 
infiltrating inflammatory cells in the stromal and epithelial tumor compartments.
3. High number of stromal NK cells and T lymphocytes (assessed by CD4, CD8 and CD3) are 
independent prognostic marker predicting good survival. This highlights the significance of 
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the tumor microenvironment as a prognostic indicator and a possible target for therapy.  
7. FUTURE PERSPECTIVES
1. A more accurate insight in the mechanism of action of inflammatory cells as well as their 
interaction with the tumor microenvironment may lead to a useful adjuvant immunotherapy in 
NSCLC. 
2.  Prospective  studies  are  essential  before  any  implementation  of  TIL  count  in  clinical 
decision  making  in  NSCLC.  This  may  pave  the  way  for  new  therapeutic  concepts  that 
augment the protective effect of anti-tumoral immune responses.
3.  Assessing  tumor  immune  status  may  be  also  of  great  importance  to  be  considered  in 
designing clinical trials of emerging therapies, because those patients who are predicted to do 
well anyway (due to a favorable immunological infiltrate) may not gain significant benefit 
from trial therapies, this will create a bias which diminishes the benefit from the trial.40 
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